Alnylam Pharmaceuticals (NASDAQ:ALNY) Downgraded by StockNews.com to “Hold”

StockNews.com lowered shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a buy rating to a hold rating in a report issued on Thursday.

Other analysts have also issued research reports about the stock. Citigroup increased their price objective on shares of Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Cantor Fitzgerald reiterated a “neutral” rating and issued a $220.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, October 11th. Barclays increased their price objective on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a research note on Friday, November 1st. Scotiabank increased their price objective on shares of Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the stock a “sector outperform” rating in a research note on Friday, November 1st. Finally, The Goldman Sachs Group raised shares of Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their price target for the stock from $198.00 to $370.00 in a report on Friday, August 16th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and eighteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $298.09.

Alnylam Pharmaceuticals Trading Up 0.2 %

Shares of Alnylam Pharmaceuticals stock opened at $253.74 on Thursday. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. Alnylam Pharmaceuticals has a 12-month low of $141.98 and a 12-month high of $304.39. The firm has a market capitalization of $32.73 billion, a price-to-earnings ratio of -96.85 and a beta of 0.39. The firm’s 50 day simple moving average is $271.93 and its two-hundred day simple moving average is $240.19.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The business had revenue of $500.90 million for the quarter, compared to analyst estimates of $532.91 million. During the same quarter last year, the firm earned $1.15 EPS. The company’s quarterly revenue was down 33.3% compared to the same quarter last year. Analysts predict that Alnylam Pharmaceuticals will post -2.21 EPS for the current year.

Insider Buying and Selling

In related news, CEO Yvonne Greenstreet sold 5,219 shares of the firm’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $1,309,864.62. Following the completion of the sale, the chief executive officer now directly owns 78,880 shares in the company, valued at approximately $19,797,302.40. This trade represents a 6.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Tolga Tanguler sold 1,469 shares of the firm’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $368,689.62. Following the sale, the executive vice president now owns 13,191 shares of the company’s stock, valued at approximately $3,310,677.18. The trade was a 10.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 8,370 shares of company stock worth $2,100,703. Insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

A number of institutional investors have recently made changes to their positions in ALNY. Ashton Thomas Private Wealth LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the second quarter valued at about $26,000. Huntington National Bank increased its position in shares of Alnylam Pharmaceuticals by 91.8% during the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 45 shares during the last quarter. Hollencrest Capital Management acquired a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at about $29,000. Washington Trust Advisors Inc. acquired a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at about $42,000. Finally, True Wealth Design LLC increased its position in shares of Alnylam Pharmaceuticals by 15,300.0% during the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 153 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.